Pre-made Ecromeximab benchmark antibody (Whole mAb, anti-ganglioside GD3 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-ganglioside GD3 therapeutic antibody (Pre-made Ecromeximab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of malignant melanoma.[1][2]
| Products Name (INN Index) | Pre-Made Ecromeximab Biosimilar, Whole Mab: Anti-Ganglioside Gd3 therapeutic antibody |
|---|---|
| INN Name | ecromeximab |
| Target | ganglioside GD3 |
| Format | Whole mAb |
| Derivation | Chimeric |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 – kappa |
| VD LC | IgG1 – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Ludwig?Institute?for Cancer?Research (New York NY USA) / Life?Science Pharmaceuticals (LSP) (Darien CT USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | YB2/0 cell line: low fucosylation |
| Previous Name | NA |
| Gm Offical Target Name | ganglioside GD3 |
| Package |
